Press Releases

Phenex enters into a Research Collaboration and License Agreement with Janssen
for Autoimmune and Chronic Inflammatory Disorders
Phenex will receive an upfront payment and is eligible ...
[2012-12-17]
Phenex und Janssen vereinbaren eine Forschungskooperation in Verbindung
mit einem Lizenzabkommen auf dem Gebiet von
Autoimmun- und Chronisch Entzündlichen Erkrankungen
Phenex erhält eine Upfront-Zahlung und kann erfolgs- und ...
[2012-12-17]
Phenex reports successful completion of Phase I Studies with FXR-Agonist Px-102
and publishes research progress in two independent papers
On the back of the good scientific news, Phenex raises 5 Mio Euro...
[2012-10-31]
Phenex schließt erfolgreich die Phase I - Entwicklung ihres FXR-Agonisten Px-102 ab
und publiziert neue Forschungsergebnisse
Auf Basis dieser ermutigenden Datenlage wirbt Phenex 5 Mio Euro...
[2012-10-31]
Phenex initiates Phase I first-in-man study with its clinical development candidate Px-102
The FXR agonist Px-102 might open new avenues for the treatment of Non-Alcoholic Steatohepatitis (NASH)...
[2011-09-15]
Phenex beginnt die klinische Phase I Erstanwendungsstudie für den Entwicklungskandidaten Px-102
Der FXR-Agonist Px-102 eröffnet neue Behandlungsmöglichkeiten für Nichtalkoholische Steatohepatitis (NASH)...
[2011-09-15]
Phenex wins Prof. Dr. med Dr. rer. nat. Werner Kramer as scientific advisor
Phenex and Prof Kramer will jointly develop Phenex´ FXR agonist Px-102...
[2011-07-20]
Phenex gewinnt Prof. Dr. med Dr. rer. nat. Werner Kramer als wissenschaftlichen Berater
Phenex und Prof. Kramer gehen gemeinsam die klinische Entwicklung von Px-102...
[2011-07-20]



































Prof Kramer
Phenex closes 6 Mio € Series C financing round
[2010-09-21]
Phenex receives 1.4 Mio Euro BioChance Grant.
Phenex AG develops novel indications for FXR-targeted drugs and wins Prof. Dr. Michael Trauner as...
[2009-07-02]
Prof. Dr. Bernd Wetzel becomes Head of Phenex´ Scientific Advisory Board.
Phenex Pharmaceuticals AG today announced that Prof. Dr. Bernd Wetzel will become...
[2009-04-08]
Phenex AG and Biogen Idec enter into a milestone-based target to lead collaboration.
Biogen Idec uses Phenex' expertise to identify...
[2008-12-03]
Phenex AG closes 11,5 M USD (8,2 M Euro) financing round.
A syndicate of institutional and private investors...
[2008-10-02]
Phenex AG provides drug profiling services to Sanofi Aventis.
Phenex uses its Nuclear Receptor assay battery...
[2007-05-09]
Phenex AG provides compound profiling services to Bayer-Schering Pharma AG.
Phenex uses its SNuRM® platform to support...
[2007-02-08]
Phenex AG obtains four patents relevant for its drug discovery efforts.
The nuclear receptor-based drug discovery company starts...
[2006-03-08]
Phenex AG closes first equity funding round.
Phenex Pharmaceuticals announced today the closing of its first equity financing round...
[2005-10-10]
Phenex AG widens customer base, maintains profitability and recruits further laboratory staff.
Additional business by acquiring a list of new customers worldwide...
[20005-07-28]
Phenex licences Nuclear Receptor Research Toolbox to Roche.
Fruitful collaboration with Roche is continued...
[2004-05-14]
Phenex launches RE-PheXTM.
A unique software tool for the genome wide prediction of candidate target genes...
[2003-12-03]
Phenex acquires Nuclear Receptor Assets from LION.
Phenex founders’ team performs a “true” management buy-out...
[2003-11-13]
Phenex and Roche enter into research collaboration.
Phenex is tasked to profile novel Roche compounds using
the SNuRM® Technology...
[2003-06-16]